The purpose of this study was to determine the effect of dutasteride on quality of life of men with lower urinary tract symptoms associated with enlarged prostate or benign prostatic hyperplasia (BPH) as measured by symptom problem index (SPI), BPH-specific interference with activities (BSIA), BPH-specific psychological well-being (BPWB) and BPH-specific lifestyle adaptations (BSLA). Data were derived from three randomized, double-blind studies conducted in 4325 men treated with placebo or dutasteride (0.5 mg/day). Primary analyses included changes from baseline in mean SPI, BSIA, BPWB and BSLA scores. Men treated with dutasteride showed significant improvements in SPI, BSIA, BPWB and BSLA scores compared with placebo.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Roehrborn CG, Marks L, Harkaway R . Enlarged prostate: a landmark national survey of its prevalence and impact on US men and their partners. Prostate Cancer Prostatic Dis 2006; 9: 30–34.
Emberton M, Andriole GL, de la Rosette J, Djavan B, Hoefner K, Vela Navarette R et al. Benign prostatic hyperplasia: a progressive disease of aging men. Urology 2003; 61: 267–273.
Girman CJ, Jacobsen SJ, Rhodes T, Guess HA, Roberts RO, Lieber MM . Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35: 277–284.
Arocho R, McMillan CA, Sutton-Wallance P . Construct validation of the USA–Spanish version of the SF-36 health survey in a Cuban-American population with benign prostatic hyperplasia. Qual Life Res 1998; 7: 121–126.
Spencer S, Calverly PM, Sherwood Burge P, Jones PW, for the ISOLDE Study Group. Inhaled steroids in obstructive lung disease. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163: 122–128.
Girman CJ, Epstein RS, Jacobsen SJ, Guess HA, Panser LA, Oesterling JE et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44: 825–831.
Tenover JL, Pagano GA, Morton AS, Liss CL, Byrnes CA, on behalf of the Primary Care Investigator Study Group. Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Clin Ther 1997; 19: 243–258.
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998; 338: 557–563.
Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G, on behalf of the ARIA3001, ARIA3002 and ARIA3003 Study Investigators. Efficacy and safety of a dual inhibitor of 5α-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60: 434–441.
Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S . Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5α-reductase inhibitor. J Clin Endocrinol Metab 2004; 89: 2179.
Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549–1557.
Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK . Measuring disease-specific health status in men with benign prostatic hyperplasia. Med Care 1995; 33 (4 Suppl): AS145–AS155.
Epstein RS, Deverka PA, Chute CG, Panser L, Oesterling JE, Lieber MM et al. Validation of a new quality of life questionnaire for benign prostatic hyperplasia. J Clin Epidemiol 1992; 45: 1431–1445.
Chapple CR . Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician. BJU Int 2004; 94: 738–744.
Roehrborn CG, Lukkarinen O, Mark S, Siami P, Ramsdell J, Zinner N . Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5α-reductase inhibitor dutasteride: results of 4-year studies. BJU Int 2005; 96: 572–577.
Roehrborn CG, O'Leary M, Black L . Measurement of the effect of dutasteride on worry and embarrassment associated with lower urinary tract symptoms in men with BPH: use of a novel instrument [poster]. Presented at the European Association of Urology 2005 Meeting, 19 March 2005 Istanbul, Turkey.
O'Leary MP, Roehrborn C, Andriole G, Nikel C, Boyle P, Höfner K . Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5α-reductase inhibitor. BJU Int 2003; 92: 262–266.
We gratefully acknowledge Grace Johnson, PharmD, Scientific Therapeutics Information Inc, Springfield, New Jersey, and thank her for providing editorial assistance in preparing this manuscript. Phase III studies and preparation of this manuscript were funded by GlaxoSmithKline.
About this article
Cite this article
O'Leary, M., Roehrborn, C. & Black, L. Dutasteride significantly improves quality of life measures in patients with enlarged prostate. Prostate Cancer Prostatic Dis 11, 129–133 (2008). https://doi.org/10.1038/sj.pcan.4500990
This article is cited by
Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis
World Journal of Urology (2014)
Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies
World Journal of Urology (2014)
Gene Expression Profiling Reveals Regulation of ERK Phosphorylation by Androgen-Induced Tumor Suppressor U19/EAF2 in the Mouse Prostate
Cancer Microenvironment (2013)